Camptothecins and their novel anticancer properties evaluated by using pass method.
Cancer is a kind of disease characterized by uncontrolled cell growth and spread of the abnormal cells, and is caused by acquired genetic alternations of somatic cells. Currently, there are several approaches used for cancer treatment such as: Surgery, Chemotherapy, Immuno-therapy (monoclonal--antibody), Radiotherap and Gene-therapy. Most of the drugs being used tody in chemotherapy have natural origins and were first discovered in plants,fruits or microorganisms. Therefore,Plants are important source of anticancer molecules which target different pathways of cancer progression.Camptotheca (Happy tree)is a genus of medium-sized deciduous,mainly found in southern of China and Tibet.There are two species of Camptotheca (i.e. Camptotheca acuminata and Camptotheca lowreyana). Camptotheca acuminata species is rich of new antineoplastics agents, for instance: Camptothecin(CPT), Irinotecan, Topotecan, 9-Nitrocamptothecinand 10-Hydroxycamptothecine. Camptothecin is the first compound in this class extracted from bark and leaves of Camptotheca acuminate tree species. Irinotecan and Topotecan are semisynthetic analogue of natural alkaloid Camptothecin ,and currently are the most widely used camptothecin analogs in clinical experiments that targets topoisomerase I enzyme. 9-Nitrocamptothecin and Hydroxycamptothecin(10-HCPT) are analogs of the natural Camptothecin family.
Previous investigations of scientics in the world have releaved that Camptothecin(CPT), 10-Hydroxycamptothecin(10-HCPT), 9-Nitrocamptothecin inhibit topoisomerase I enzyme in order to have anticancer properties. Topoisomerase I is a nuclear enzyme that breaks unwinds the positive super coils of DNA. Subsequently, the break is sealed and the linkage number is changed by 1, and permit essential cellular process (i.e DNA replication, recombination,repair and transcription )to occur.The camptothecins definitely bind to topoisomerase I and stabilize DNA-topoisomerase I cleavable complex. Currently this study is focused on another target of Camptothecin (CPT), 10-Hydroxycamptothecin (10-HCPT), 9-Nitrocamptothecin molecules. Morever, Bioinformatics tools such as PASS are applied to predict bioactivities and properties of these anticancer agents. We believe that it can be as an approach in order to recognize the new mechanisms of action of anticancer compounds.
Material and Method
A paractical database is the main step in bioinformatics projects. Collection of data from Pubmed database were accomplished with general keyword "anticancer". Most data were gathered from 2010 papers; therefore, anticancer molecules were extracted from this papers ,and defined their targets in apoptotic pathway. In this case molecules were classified based on their origins ,as a result we had 7 groups of anticancer molecule such as molecules in Drug Bank, plants, fruits, microorganisms, semisythetic agents, synthetic agents and finaly ungrouped anticancer agents which their origins were unknown.
Structural formula of these molecules were investigated from Chemspider, Pubcheme and Wikipedia, respectively ,and the orginal molecular structure of all compounds were found, their skeletal structures drawn with Chemschetch, Chemaxon, version 5.4 software in order to reach 3D structures of molecules within MDL SD file, the same software is used with molecular mechanics algorithm for structural optimization. CherriAxon is a leader in providing Java based chemical software development platform for biotechnology and pharmaceutical industries. Protein Data Bank (PDB), Tripos MOL2, MDL MOL and SD file formats were saved, too (figure 1).
[FIGURE 1 OMITTED]
All molecules were predicted for their possible bioactivities with PASS, V.poroikov et al, version 1.917, software.PASS (Predicition of Activity Spectra for Substance ) is a simple computational tool that can predict more than 1500 pharmacological effects, molecular mechanisms of action, and toxicities on basis of structural descriptors of compounds. The top molecules with more than 0.6 score anticancer activity were selected and categorized on basis of their targets.
Results and Discussions
Screening is basis of this project which was applied at each step. About 292 molecules were gathered from searched papers, and PubChem, Chemspider database were looked for finding structural formulas of these screened molecules. Accordingly, nearly 242 molecules had available formula structure, were evaluated with PASS in order to predict comounds with high anticancer activity. All Camptothecins exhibited anticancer activities more than 0.6 score and were screened. Figure 2 exhibits platform of PASS software with anticancer analysis of Camptothecins.
[FIGURE 2 OMITTED]
Camptothecins with their docking score of their antineoplatic, topoisomerase I inhibitory, DNA intercatalor activity are shown in Tables 1,2 and 3. Also drug-likenesses were derived by PASS software in order to estimate cytotoxicity of camptothecins compounds. Figures 3,4 and 5 represented the docking score of Camptothecins in details.
Figure 3 depicts antineoplastic alkaloid activities of Camptotheicns and it is mentioned that they have a strong antineoplastic alkaloid activities. However ,no significant difference was observed among their scores.
[FIGURE 3 OMITTED]
As can be seen from Figure 4, all of the Camptothecins are potent topoisomerase I inhibitors and all of them show this property more 0.781 . Morever,the frequency of topoisomerase inhibitory isn't so different among them.
[FIGURE 4 OMITTED]
According to Figure 5 ,the most potent property that Camptothecins have showed , is DNA intercatalor activity.
[FIGURE 5 OMITTED]
Previous papersdemonstrated that Camptothecins have anticancer activities, scientists mentioned antineoplatic and topoisomerase I inhibitor activity of Camptothecins (12). It is suggested that Camptothecin interact with the enzyme /DNA complex through hydrogen bonds. On the other hand, Topotecan acts through forming a stable covalant complex with DNA/TOP-1 complex, in order to breaks in DNA strand. This results in apoptosis and cell death. In addition, Camptothecins have a dose limiting side effects, because of this, they are applied in many cancers for instance (Reference 21)10-Hydroxycamptothecin and Camptothecin are used in breast cancer and targets MCF-7 cells, also 10-Hydroxycamptothecin (Refrence 6)is applied in human colon cancer and arrested Colo 205 cells in G2 phase of cell cycle and induces apoptosis through caspase-3 dependent pathway . So, analysis of Camptothecins with PASS could predict more properties of these molecules and highlighted their toxicities. As a result, three main characterstics of molecules were antineoplastic alkaloid activities, topoisomerase I inhibitory and DNA intercatalor potency. Among Camptotheicns family, Irinotecan showed the highest antineoplatic alkaloid activity with 0.807 score. However, Topotecan had the lowest antineoplatic alkaloid activity with 0.615 score , but no significant difference was observed among their scores. Camptothecins are potent topoisomerase I inhibitors and all of them show this property more 0.781 score. Although, Camptothecin exhibited the highest topoisomerase I inhibitor activity with 0.952, 10-Hydroxycamptothecin also releaved high score of topoisomerase I inhibitor potency 0.948. The highest bioactivity that Camptothecins show is DNA intercatalor activity as well as prediction scores releaved that Camptothecin with 0.972 score was the most potent DNA intercatalor agent. Likewise, 10-Hydroxycamptothecin with 0.961 also was as a potent DNA intercatalor agent too.
It is noteworthy that the mean score of each molecule was higher than 0.77 and it was indicated that all of them were potent anticancer agents that definitely were antineoplastics, topoisomerase I inhibitor and DNA intercatalor agents. Interestingly, both of the Camptothecin and 10-Hydroxycamptothecin had the same mean score ,and they were the most potent agents between the other Camptothecins. These comounds releaved Drug likenesses score were higher than 0.9. It means that they are as suitable drugs in chemotherapy. The detailed analysis of these compounds and their derivatives may improve our knowledge in finding new candidate anticancer drugs.
(1.) Bruton, L., S.J. Lazo, L. Park, K. Goodman & Gilman's, 2005. The Pharmacological Basis of Therapeutics. Eleventh Edition.
(2.) Strachan, T., Read A, 2011. Human Molecular Genetics ,Fourth Edition.
(3.) Chakraborti, K.A., R. Thilagavathi, 2003. Computer-Aided Design of Selective COX2-Inhibitor: Molecular Docking of Structurally Diverse Cyclooxygenase-2 Inhibitors using FlexX Method, Internet Electron. J. Mol., 1,000-000.
(4.) Hyde, D., Introduction to Genetics Principles, 2009.
(5.) Pantazis, P., Z. Han, K. Balan, Y. Wang, J.H. Wyche, 2003. Camptothecin and 9-nitrocamptothecin (9NC) as anti-cancer, anti-HIV and cell-differentiation agents. Development of resistance, enhancement of 9NC-induced activities and combination treatments in cell and animal models, Anticancer Res., 23(5A): 3623-38.
(6.) Ping, Y.H., H.C. Lee, J.Y. Lee, P.H. Wu., L.K. Ho., C.W. Chi, M.F. Lu., J.J. Wang, 2006. Anticancer effects of low-dose 10-hydroxycamptothecin in human colon cancer. Oncol Rep., 15(5): 1273-9.
(7.) Takasaki, M., T. Konoshima, K. Komatsu, H. Tokuda, H. Nishino, 2000. Anti-tumor-promoting activity of lignans from the aerial part of Saussurea medusa. Cancer Lett., 158(1): 53-9.
(8.) Bae, K.E., H.S. Chong, D.S. Kim, Y.W. Choi, Y.S. Kim, Y.K. Kim, 2010. Compounds from Viburnum sargentii Koehne and evaluation of their cytotoxic effects on human cancer cell lines. Molecules, 15(7): 4599-609.
(9.) Gao, H., B. Liu, F. Liu, Y. Chen, 2010. Anti-proliferative effect of camellianin A in Adinandra nitida leaves and its apoptotic induction in human Hep G2 and MCF-7 cells. Molecules, 15(6): 3878-86.
(10.) Hu, X., K.V. Balan, N. Ramos-DeSimone, J.H. Wyche, Z. Han, P. Pantazis, 2003. Differential susceptibility to 9-nitrocamptothecin (9-NC)induced apoptosis in clones derived from a human ovarian cancer cell line: possible implications in the treatment of ovarian cancer patients with 9NC. Anticancer Drugs, 14(6): 427-36.
(11.) Pommier, Y. I. Topoisomerase, 2006. inhibitors: camptothecins and beyond. Nat Rev Cancer, 6(10): 789-802.
(12.) Minoo Robati, David Holtz, and Charles J. Dunton, 2008. A review of topotecan in combination chemotherapy for advanced cervical cancer. Ther Clin Risk Manag., 4(1): 213-218.
(13.) Sam, Zwenger and Chhandak Basu, 2008. Plant terpenoids: applications and future potentials. Biotechnology and Molecular Biology Reviews, 3 (1): 001-007.
(14.) Zhang, Z., S. Li, S. Zhang, C. Liang, D. Gorenstein, R.S. Beasley, 2004. New camptothecin and ellagic acid analogues from the root bark of Camptotheca acuminata. Planta Med., 70(12): 1216-21.
(15.) Kollmannsberger, C., K. Mross, A. Jakob, L. Kanz, C. Bokemeyer, 1999. Topotecan--A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology, 56(1): 1-12.
(16.) Nagashima, G., T. Fujimoto, T. Miyo, J. Asai, R. Suzuki, 2000. [Irinotecan (topoisomerase-I inhibitor) for the treatment of recurrent primary intracranial malignant lymphoma]. Gan To Kagaku Ryoho., 27(3): 479-85.
(17.) Mathijssen, R.H., W.J. Loos, J. Verweij, A. Sparreboom, 2002. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets, 2(2): 103-23.
(18.) Zhang, R., Y. Li, Q. Cai, T. Liu, H. Sun, B. Chambless, 1998. Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I. Cancer Chemother Pharmacol., 41(4): 257-67.
(19.) Shimada, Y., M. Rothenberg, S.G. Hilsenbeck, H.A. Burris, 1994. 3rd, Degen D, Von Hoff DD. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs, 5(2): 202-6.
(20.) Chatterjee, D., I. Schmitz, A. Krueger, K. Yeung, S. Kirchhoff, P.H. Krammer et al., 2001. Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation ofc FLIP(short). Cancer Res., 61(19): 7148-54.
(21.) Liu, W., R. Zhang, 1998. Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. Int J Oncol., 12(4): 793-804.
(22.) Main, C., L. Bojke, S. Griffin, G. Norman, M. Barbieri, L. Mather, D. Stark, S. Palmer, R. Riemsma, 2006. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Health Technol. Assess., 10(9): 1-132. iii-iv.
(23.) Vrdoljak, A.L., S. Berend, D. Zeljezic, J. PiljacZegarac, S. Plestina, K. Kuca, B. Radic, M. Mladinic, N. Kopjar,2009. Irinotecan side effects relieved by the use of HI-6 oxime: in vivo experimental approach. Basic Clin Pharmacol Toxicol., 105(6):401-9.
(24.) Ilson, D.H., B. Minsky, Irinotecan in esophageal cancer. Oncology (Williston Park), 17(9 Suppl 8): 32-6.
(25.) Xu, Y., M.A. Villalona-Calero, 2002. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol., 13(12): 1841-51.
 Behrangi N.,  Hashemi M.,  Doustar Y. and  Borna H.
--Department of Genetics, Tehran Medical Branch, Islamic Azad University, Tehran, Iran.
--Department of veterinary Pathobiology, Tabriz Branch, Islamic Azad University, Tabriz, Iran.
Hashemi M., Department of Genetics, Tehran Medical Branch, Islamic Azad University, Tehran, Iran.
Table 1. Pass prediction of antineoplastic property Molecules Pass activity Pass inactivity (antineoplastic) (antineoplastic) A Camptothecin 0.712 0.002 B Irinotecan 0.807 0.002 C Topotecan 0.615 0.002 D 10-Hydroxycamptothecin 0.720 0.002 E 9-Nitrocamptothecin 0.619 0.002 Molecules Drug likeness A Camptothecin 0.990 B Irinotecan 0.992 C Topotecan 0.989 D 10-Hydroxycamptothecin 0.991 E 9-Nitrocamptothecin 0.950 Table 2. PASS prediction of topoisomerase I inhibitor activity Molecules Pass activity Pass inactivity (Topoisomerase I (Topoisomerase I inhibitory) inhibitory) A Camptothecin 0.952 0.001 B Irinotecan 0.781 0.002 C Topotecan 0.846 0.002 D 10-Hydroxycamptothecin 0.948 0.001 E 9-Nitrocamptothecin 0.858 0.002 Table 3. PASS prediction of DNA intercatalor activity Molecules Pass activity Pass inactivity (DNA intercatalor (DNA intercatalor activity) activity) A Camptothecin 0.972 0.001 B Irinotecan 0.816 0.002 C Topotecan 0.874 0.002 D 10-Hydroxycamptothecin 0.961 0.001 E 9-Nitrocamptothecin 0.885 0.002
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Original Article|
|Author:||Behrangi, N.; Hashemi, M.; Doustar, Y.; Borna H.|
|Publication:||Advances in Environmental Biology|
|Date:||Aug 1, 2011|
|Previous Article:||Effect of gibberellic acid on the speed and percentage of germination and vascular tissue ontogenesis in Helianthus annuus L.|
|Next Article:||Hematologic and serologic changes following ivermectin treatment in mange infested West African Dwarf goats.|